S&P Futures
4,410.50 +11.25 (+0.26%) Dow Futures
34,400.00 +56.00 (+0.16%) Nasdaq Futures
15,009.00 +50.50 (+0.34%) Russell 2000 Futures
1,860.70 +4.10 (+0.22%) Crude Oil
78.51 -1.13 (-1.42%) Gold
1,932.40 +6.40 (+0.33%)
Novo Nordisk A/S (NVO)
Pre-Market:
| Previous Close | 185.87 |
| Open | 184.44 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 183.86 - 185.77 |
| 52 Week Range | 95.02 - 192.18 |
| Volume | |
| Avg. Volume | 1,490,750 |
| Market Cap | 414.187B |
| Beta (5Y Monthly) | 0.29 |
| PE Ratio (TTM) | 42.53 |
| EPS (TTM) | 4.35 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.06 (1.12%) |
| Ex-Dividend Date | Aug 18, 2023 |
| 1y Target Est | 187.30 |
Yahoo FinanceLarge employers split on covering GLP-1 drugs for weight loss: Survey
Mental health concerns could increase cost for employers, along with expensive, popular weight loss drugs, for 2024, a new survey says.
- Reuters
Novo hires Thermo Fisher as 2nd manufacturer for Wegovy weight-loss drug - source
Novo Nordisk has hired Thermo Fisher as its second contract manufacturer for its hugely popular weight-loss drug Wegovy, a source familiar with the matter told Reuters. Thermo is doing the filling of the Wegovy injection pens at its factory in Greenville, North Caroline, the source said, declining to be named because the information is confidential. Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in May the company had signed up a second contract manufacturer in the United States, but the identity of the company has not previously been reported.
Motley FoolCould This 1 Problem Put a Dent in Novo Nordisk and Eli Lilly Stock?
As you've probably noticed, the big pharma juggernauts Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are both making headlines with their wonder drugs for obesity and diabetes. Both Eli Lilly and Novo Nordisk have multiple drug development programs attempting to find a treatment for non-alcoholic steatohepatitis, a chronic liver condition more commonly known by its acronym, NASH. As many as 6.5% of people living in the U.S. today have the condition, so it's a major potential market that isn't yet addressed by any medicine.
